Image Analysis Group (IAG), a global leader in clinical trial imaging and AI-driven biomarkers, is enhancing its footprint in the United States by launching a new office in Cambridge, Massachusetts. This strategic move positions IAG closer to the hub of biotechnology and pharmaceutical companies in the Boston area, facilitating stronger collaborations and offering localized support for clinical trials throughout the region.
The establishment of the Cambridge office is poised to bolster IAG’s efforts across a range of therapeutic areas, such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. This new location aims to enhance the company’s ability to work directly with sponsors and contract research organizations engaged in Phase I–III clinical trials and imaging-intensive development programs. Moreover, IAG plans to generate local job opportunities, with roles anticipated in clinical imaging operations, data science, regulatory support, and business development within the next 12 to 24 months.
IAG’s expansion in the Boston life-sciences ecosystem is expected to foster improved collaboration with biotechnology firms, pharmaceutical companies, academic institutions, and clinical research centers. The Cambridge office will support IAG’s comprehensive imaging services, which include clinical trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery.
Globally, Image Analysis Group operates across North America, Europe, and the Asia-Pacific region, collaborating with pharmaceutical, biotechnology, and medtech companies, as well as contract research organizations, on multi-center studies. The company’s international operations are structured to deliver standardized imaging protocols, centralized data harmonization, and consistent imaging analysis for trials conducted worldwide.
Founded in 2007 and headquartered in London, IAG functions as an imaging Clinical Research Organization (iCRO). It partners with pharmaceutical, biotechnology, and medical technology companies to support imaging-based clinical trial endpoints. IAG’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial management. For further information, visit their website at www.ia-grp.com or contact their press representative, Marie Fussell, at +1 267-857-8638 or [email protected].
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.